From: Conbercept for patients with age-related macular degeneration: a systematic review
Study ID | Study design | Participants | N | Intervention group (N) | Comparison group (N) | Outcomes | Follow-up time after the first treatment (months) |
---|---|---|---|---|---|---|---|
Li YY, 2017 [17] | RCT | wet AMD | 54 | Conbercept (27) | Conservative treatment (27) | ②④ | 6 |
Mei HY, 2017 [18] | RCT | wet AMD | 66 | Conbercept (33) | Conservative treatment (33) | ② | NA |
Song W, 2016 [19] | RCT | wet AMD | 112 | Conbercept (56) | Conservative treatment (56) | ②④ | 6 |
Liu ZN, 2016 [20] | RCT | wet AMD | 40 | Conbercept (20) | Ranibizumab (20) | ② | 12 |
Zhang HX, 2016 [21] | RCT | wet AMD | 50 | Conbercept (25) | Ranibizumab (25) | ②③④ | 1 |
Liu R, 2015 [22] | RCT | wet AMD | 60 | Conbercept (30) | Ranibizumab (30) | ②③ | 3 |
Wang NF, 2017 [23] | RCT | wet AMD | 76 | Conbercept (38) | Ranibizumab (38) | ①② | 3 |
Lyu P, 2016 [24] | RCT | wet AMD | 84 | Conbercept (42) | Ranibizumab (42) | ①②④ | 3 |
Zheng MW, 2017 [25] | RCT | wet AMD | 85 | Conbercept (42) | Ranibizumab (43) | ①② | 3 |
Wang XX, 2015 [26] | RCT | wet AMD | 60 | Conbercept (30) | Transpupillary thermotherapy (30) | ② | 6 |
Qin MM, 2016 [27] | RCT | wet AMD | 82 | Conbercept (41) | Transpupillary thermotherapy (41) | ② | 3 |
Li L, 2017 [28] | RCT | wet AMD | 86 | Conbercept (43) | Transpupillary thermotherapy (43) | ②④ | 6 |
Zhang X, 2015 [29] | RCT | wet AMD | 98 | Conbercept (49) | Transpupillary thermotherapy (49) | ② | 6 |
Zhu Y, 2017 [30] | RCT | wet AMD | 50 | Conbercept (25) | Triamcinolone acetonide (25) | ①②④ | 3 |
He XT, 2015 [31] | RCT | wet AMD | 60 | Conbercept (30) | Triamcinolone acetonide (30) | ①②④ | 3 |
Han X, 2017 [32] | RCT | wet AMD | 70 | Conbercept (35) | Triamcinolone acetonide (35) | ①②④ | 3 |
Pan XL, 2017 [33] | RCT | wet AMD | 76 | Conbercept (38, 42eyes) | Triamcinolone acetonide (38, 38eyes) | ② | 12 |
Yue JL, 2017 [34] | RCT | wet AMD | 76 | Conbercept (38) | Triamcinolone acetonide (38) | ② | 12 |